New approach will help identify drugs that can ‘glue’ proteins together

A new screening method that can test the effectiveness of therapeutic molecules designed to ‘glue’ proteins together in the body has been developed by researchers at the University of Birmingham and the University of Leicester. The research paves the way for drug developers to screen large numbers of potential new drug compounds to discover new treatments for diseases such as breast cancer and Parkinson’s disease.

The ways in which proteins interact with each other are fundamental to all cell functions. These interactions underpin every function of a healthy body, with any slight change in these interactions resulting in disease.

A handful of drugs have been designed that can break apart these interactions, and this serves to disrupt the progress of the disease. However, in some diseases, the problem is caused by protein interactions not happening, or not happening in the right way. So new drugs that work by ‘gluing’ these proteins together would be highly effective, but finding them is not straightforward.

In this study, published in Chemical Science, researchers from the University of Birmingham’s School of Biosciences have designed a system that uses mass spectrometry to measure the precise mass of a pair of proteins, plus the ‘glue’, to identify which ‘glue’ is the strongest and thus will likely be the most successful in treating the disease.

Lead author Dr Aneika Leney said: “A healthy body depends very much on the cells’ proteins being able to signal effectively. Any wrong signal can lead to disease and that could be the wrong proteins sticking together – or proteins not joining up as they should. We want a drug that corrects for this. Our methods provides a ‘snapshot’ of what is happening to the proteins when we add a potential drug so we can see quickly whether the ‘glue’ is working.”

Co-lead author of the study Dr Doveston said: “Looking for molecules that act as glues is not easy because things are complicated by having two proteins in the mix. At the early stage of development we often just want to find molecules that are good starting points for development, so they might not be that good as glues at this stage. The current high-throughput screening methods available to us are usually not very effective in this context. The mass spectrometry method is great because we can learn so much from the data and it can be gathered relatively easily and quickly. Because the glue compounds are highly specific to the identified proteins, interactions with other proteins are rare, so the therapy is unlikely to produce any unlooked-for effects.”

Image credit: Adrien Converse

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free